Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00600769 · ClinicalTrials.gov registry record · Phase 4

Clarithromycin for the Treatment of Infections Caused by Nontuberculous Mycobacteria (NTM)

A Phase 4 study of Nontuberculous Mycobacteria and Mycobacterium Avium Complex, sponsored by The University of Texas Health Science Center at Tyler.

Completed
Registry status
Phase 4
Development phase
210
Enrollment target
1
Study location

NCT00600769 is a Phase 4 study of Nontuberculous Mycobacteria and Mycobacterium Avium Complex that has completed, run by The University of Texas Health Science Center at Tyler. The registered enrollment target is 210 participants. The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00600769, a Phase 4 study of Nontuberculous Mycobacteria and Mycobacterium Avium Complex, has completed, sponsored by The University of Texas Health Science Center at Tyler.

COMPLETED
Registry status
Phase 4
Development phase
210 participants
Enrollment target
1
Study location

Study Summary

Use of oral clarithromycin for treatment of chronic lung disease due to Mycobacterium avium-intracellulare and other non-tuberculous Mycobacteria

Interventions

  • DRUG Clarithromycin

Study Locations (1)

Texas

  • The University of Texas Health Science Center at Tyler - Tyler

Trial Details

FieldValue
Enrollment Target 210 participants
Start Date 1991-01
Est. Completion 2017-05-18
Phase Phase 4

What the Registry Record Tells You About NCT00600769

The ClinicalTrials.gov registry entry for NCT00600769 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 210 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is The University of Texas Health Science Center at Tyler, which has 7 total studies on file at ClinicalTrials.gov.

The record links to 2 conditions, with Nontuberculous Mycobacteria appearing as the primary indexed condition, and to 1 intervention - of which Clarithromycin is the first listed.

NCT00600769 reports 1 study location spanning 1 distinct geographic area - top geographies include Texas.

Frequently Asked Questions

What is clinical trial NCT00600769 about?

NCT00600769 is a clinical study titled "Clarithromycin for the Treatment of Infections Caused by Nontuberculous Mycobacteria (NTM)". Use of oral clarithromycin for treatment of chronic lung disease due to Mycobacterium avium-intracellulare and other non-tuberculous Mycobacteria

What is the current status of trial NCT00600769?

This trial is currently completed. It is a Phase 4 study. The enrollment target is 210 participants. The study started on 1991-01. Estimated completion is 2017-05-18.

What conditions does trial NCT00600769 study?

This clinical trial studies the following conditions: Nontuberculous Mycobacteria, Mycobacterium Avium Complex.

What interventions are being tested in trial NCT00600769?

The interventions under investigation include: Clarithromycin (DRUG).

Who is sponsoring clinical trial NCT00600769?

This trial is sponsored by The University of Texas Health Science Center at Tyler, which has 7 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00600769 being conducted?

This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Nontuberculous Mycobacteria

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.